Form 4: Tourmaline Bio CEO Exits Holdings in Novartis Merger

Tourmaline Bio, Inc. CEO Sandeep Chidambar Kulkarni disposed of all beneficial ownership following the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Sandeep Chidambar Kulkarni, CEO and Director of Tourmaline Bio, Inc. (TRML), reported the disposition of all his beneficial ownership in the company.
• The disposition occurred on October 28, 2025, pursuant to an Agreement and Plan of Merger dated September 8, 2025, with Novartis AG and its subsidiary, Torino Merger Sub Inc.
• Merger Sub completed a cash tender offer to acquire all outstanding common stock of Tourmaline Bio, Inc. for $48.00 in cash per share.
• Kulkarni disposed of 724,664 shares of common stock held directly.
• An additional 30,387 restricted shares, which became fully vested immediately prior to the merger's effective time, were also disposed of directly.
• 7,000 shares held indirectly by Gilead Capital, LP, where Kulkarni's spouse is a partner, were also disposed of.
• Employee stock options with exercise prices of $7.9, $9.46, and $15.54, totaling 983,685 shares, were canceled and converted into a cash payment equal to the difference between the $48.00 merger consideration and the respective exercise price, multiplied by the number of shares.

Sentiment

Score: 8

Explanation: The filing indicates the successful completion of a merger where shareholders received a cash premium for their shares, and options were converted to cash, representing a positive outcome for the company's investors and management.

Positives

• Shareholders, including the reporting person, received a cash payment of $48.00 per share for their common stock.
• Employee stock options were converted into cash, providing liquidity to option holders.

Negatives

• Tourmaline Bio, Inc. ceases to be an independent publicly traded entity following the acquisition.

Future Outlook

Tourmaline Bio, Inc. has been acquired by Novartis AG and will no longer operate as an independent public entity. This filing reports the completion of the acquisition and the disposition of securities by an insider.

Industry Context

This transaction represents a common occurrence in the biotechnology and pharmaceutical sectors, where larger companies acquire smaller firms, often for their pipeline assets or strategic technologies. The acquisition of Tourmaline Bio by Novartis AG indicates a strategic move by Novartis to integrate Tourmaline Bio's assets.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or results within the industry.
• The $48.00 per share merger consideration is the agreed-upon price for this specific acquisition.

Related Party Transactions

• 7,000 shares of common stock were held indirectly by Gilead Capital, LP, where the reporting person's spouse is a partner and shares voting and investment power. The reporting person may be deemed an indirect beneficial owner of these shares.

Stakeholder Impact

• Shareholders received a cash payment of $48.00 per share, providing a clear exit and return on investment.
• Employees, including the CEO, had their stock options converted to cash, realizing value from their equity compensation.

Next Steps

• The reporting person no longer holds beneficial ownership in Tourmaline Bio, Inc.
• Tourmaline Bio, Inc. is now an indirect wholly-owned subsidiary of Novartis AG.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis, Merger, Acquisition, SEC Form 4, Insider Transaction, Stock Options, Common Stock, Sandeep Chidambar Kulkarni